J. Hamm

Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.

R. Gascoyne, L. Sehn, J. Connors, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

T. Owonikoko, P. Roberts, J. Hamm, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma.

R. Fisher, M. Oken, F. Shepherd, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New drug development

O. S. Zhukova, Guy Jerusalem, Robert Millham, 2012 .

2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC

H. Wakelee, C. Zhou, M. Das Thakur, 2021, Annals of Oncology.

488P Phase I trial of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in follicular lymphoma (FL), small cell lung cancer (SCLC) and castration-resistant prostate cancer (CRPC)

A. Tolcher, V. Vorobyev, A. Choudhury, 2022, Annals of Oncology.